Clinical commissioning policy: infliximab for refractory sarcoidosis (excluding neurosarcoidosis) in adults
Infliximab is recommended to be available off-label as a routine commissioning treatment option for refractory sarcoidosis within the criteria set out in this document. The policy is restricted to adults in line with the findings from the evidence review.
Source:
NHS England
SPS commentary:
A separate Clinical Commissioning Policy is available for infliximab for refractory neurosarcoidosis (200501P).